% respectively, which decreased by 4.0%. The decrease was primarily due to the more effective internal control system of The Company. Financing Costs The Company and its subsidiary ‘s financing costs in relation
incurred from deferred tax. This extra transaction was included in year ended 2017 financial statement for the net amount of THB 24 million. Revenue from Hospital Operations Revenue from hospital operations
million in Q1/2019 whereas there was no such transaction in Q1/2020. And there was an increase in reduction cost of inventory to net realizable value amounting of Baht 1.5 million in Q1/2020 compared to
decrease in expenses of beauty business. 2. Financial Performance Summary – by business Revenues by business THB’000 Consolidated Q2/2020 Q2/2019 ∆% Distributor of medical devices and equipment 430,615
deteriorate from 36% to 32% of revenue. This was not only attributed to the decrease of SW revenue but also from the rising cost of SW patients. Number of insurers increased and consequently more visits of SW
money received from the IPO after deducting the actual expenses 4. Acquisition of all ordinary shares of Modern Pharma Company Limited, "Modern Company", which is a transaction concerning asset
, decreasing by Baht 22.34 million from as of December 31, 2019. The main reason came from the decrease with the amount of Baht 207.11 million that was the transaction by ECF Power Company Limited (ECF-P). ECF-P
Acquisition of Assets and the Connected Transaction 2. Information Memorandum regarding the offering of the newly issued ordinary shares to specific investors (Private Placement) 3. Capital Increase Report Form
each transaction. (12)3 repealed; (13)2 “connected person” means the following persons; (a) connected person under the Notification concerning Conduct Which May Constitute a Conflict of Interest in the